Can Spire Healthcare’s strategic review revive its share price?
Spire Healthcare is back in focus after a strategic review in September briefly lifted its shares, but the rally has not lasted. The UK’s second-largest private healthcare provider has seen its stock lose a quarter of its value over the following seven months, while the review remains unresolved. The situation is now further complicated by changes at Mediclinic, Spire Healthcare’s largest shareholder.
Spire Healthcare shares lose momentum after early jump
The strategic review gave Spire Healthcare an immediate boost, with the shares rising 14 per cent when it was announced. Since then, the market response has turned sharply weaker, leaving investors with no clear answer on what the review will deliver. That gap between the initial reaction and the later decline is now the central market story around Spire Healthcare.
Mediclinic holds a 30 per cent stake in Spire Healthcare and is itself in the middle of a major shake-up. Its leading shareholders, Remgro and shipping giant MSC, are restructuring the business so each takes sole ownership of different regional assets. Remgro will take the South African operations, while MSC will take the Swiss Hirslanden group.
Why the shareholder backdrop matters
The changing position of Mediclinic matters because it is Spire Healthcare’s largest shareholder and a key part of the investment backdrop. The unresolved strategic review and the ownership changes at Mediclinic together add another layer of uncertainty around Spire Healthcare’s near-term direction.
Chris Gunn, director of diagnostics at Spire Healthcare, said investment in AI enabled MRI scanners is “a gamechanger” for improving availability for patients, reducing the time they are required for the diagnostic test and enhancing image quality. He said the technology also allows staff to focus more on the human connection and help patients through the experience.
AI rollout and hospital expansion
Separately, Spire Healthcare has invested in AI to create more MRI diagnostic capacity, reduce scan time and improve image quality. The private healthcare provider installed the technology in 21 hospitals in 2025, cutting scan times for certain orthopaedic MRI studies, such as knees, from around 30 minutes to 15 minutes.
The rollout has also increased scan rates from 1. 9 to 2. 3 per hour and brought the average patient wait time down to 3. 5 days. Spire Healthcare has said it is working with software partners including Siemens, Deep Resolve, Philips, Smart Speed and GE on the implementation.
What investors will watch next
The key issue for the market is whether the strategic review can produce a clearer path forward for Spire Healthcare after months of drift. For now, the share price has yet to recover the momentum seen in September, and the unresolved review remains the main event. With Mediclinic also in transition, the next move for Spire Healthcare may depend on whether those ownership changes alter the broader picture around Spire Healthcare.
